Clovis Oncology, Inc. (CLVS)

Lifshitz & Miller announces investigation on behalf of CLVS investors concerning whether CLVS adequately disclosed test data for rociletinib, CLVS' lung cancer drug.

If you are a CLVS investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at